Literature DB >> 15504846

Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria.

T T Hien1, T M E Davis, L V Chuong, K F Ilett, D X T Sinh, N H Phu, C Agus, G M Chiswell, N J White, J Farrar.   

Abstract

The first-dose pharmacokinetic properties of intramuscular (i.m.) artesunate (ARTS; 2.4 mg/kg immediately [stat], followed by 1.2 mg/kg i.m. daily) and artemether (ARM; 3.2 mg/kg i.m. stat, followed by 1.6 mg/kg i.m. daily) were compared in Vietnamese adults with severe falciparum malaria. A total of 19 patients were studied; 9 received ARTS, and 10 received ARM. ARTS was absorbed very rapidly; concentrations in plasma peaked between 1,362 and 8,388 nmol/liter (median, 5,710 nmol/liter) within 20 min of injection and then declined with a median (range) half-life (t(1/2)) of 30 (3 to 67) min. ARTS was hydrolyzed rapidly and completely to the biologically active metabolite dihydroartemisinin (DHA). Peak DHA concentrations in plasma ranged between 1,718 and 7,080 nmol/liter (median, 3,060 nmol/liter) and declined with a t(1/2) of 52 (26 to 69) min. In contrast, ARM was slowly and erratically absorbed. The absorption profile appeared biphasic. Maximum ARM concentrations in plasma ranged between 67 nmol/liter (a value close to the 50% inhibitory concentration for some Plasmodium falciparum isolates) and 1,631 nmol/liter (median, 574 nmol/liter) and occurred at a median (range) of 10 (1.5 to 24) h. There was relatively little conversion to DHA. After i.m. injection in cases of severe malaria, absorption of the water-soluble ARTS is rapid and extensive, whereas the oil-based ARM is slowly and erratically absorbed, with relatively little conversion to the more active DHA. On the basis of this pharmacological study, parenteral ARTS is preferable to ARM as an initial antimalarial therapy, particularly in the most seriously ill patients. These findings should be formally assessed by a randomized clinical trial.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15504846      PMCID: PMC525450          DOI: 10.1128/AAC.48.11.4234-4239.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria.

Authors: 
Journal:  Trans R Soc Trop Med Hyg       Date:  2001 Nov-Dec       Impact factor: 2.184

2.  The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria.

Authors:  Kenneth F Ilett; Kevin T Batty; Shane M Powell; Tran Quang Binh; Le Thi Anh Thu; Hoang Lan Phuong; Nguyen Canh Hung; Timothy M E Davis
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

3.  A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria.

Authors:  Y Suputtamongkol; P N Newton; B Angus; P Teja-Isavadharm; D Keeratithakul; M Rasameesoraj; S Pukrittayakamee; N J White
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

4.  Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquine.

Authors:  A Brockman; R N Price; M van Vugt; D G Heppner; D Walsh; P Sookto; T Wimonwattrawatee; S Looareesuwan; N J White; F Nosten
Journal:  Trans R Soc Trop Med Hyg       Date:  2000 Sep-Oct       Impact factor: 2.184

5.  Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria.

Authors:  P Newton; Y Suputtamongkol; P Teja-Isavadharm; S Pukrittayakamee; V Navaratnam; I Bates; N White
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 6.  Pharmacokinetics of artemisinin-type compounds.

Authors:  V Navaratnam; S M Mansor; N W Sit; J Grace; Q Li; P Olliaro
Journal:  Clin Pharmacokinet       Date:  2000-10       Impact factor: 6.447

7.  Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria.

Authors:  T M Davis; H L Phuong; K F Ilett; N C Hung; K T Batty; V D Phuong; S M Powell; H V Thien; T Q Binh
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

8.  Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria.

Authors:  F ter Kuile; N J White; P Holloway; G Pasvol; S Krishna
Journal:  Exp Parasitol       Date:  1993-02       Impact factor: 2.011

9.  An open randomized comparison of intravenous and intramuscular artesunate in severe falciparum malaria.

Authors:  T T Hien; N H Phu; N T Mai; T T Chau; T T Trang; P P Loc; B M Cuong; N T Dung; H Vinh; D J Waller
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 Nov-Dec       Impact factor: 2.184

10.  Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria.

Authors:  N J White; S Looareesuwan; D A Warrell; M J Warrell; D Bunnag; T Harinasuta
Journal:  Am J Med       Date:  1982-10       Impact factor: 4.965

View more
  29 in total

1.  Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations.

Authors:  Rajeev K Mehlotra; Moses J Bockarie; Peter A Zimmerman
Journal:  Eur J Clin Pharmacol       Date:  2006-11-09       Impact factor: 2.953

2.  Artemether for severe malaria.

Authors:  Ekpereonne B Esu; Emmanuel E Effa; Oko N Opie; Martin M Meremikwu
Journal:  Cochrane Database Syst Rev       Date:  2019-06-18

3.  Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea.

Authors:  Rajeev K Mehlotra; Mark N Ziats; Moses J Bockarie; Peter A Zimmerman
Journal:  Eur J Clin Pharmacol       Date:  2006-02-28       Impact factor: 2.953

4.  Artemether and artesunate show the highest efficacies in rescuing mice with late-stage cerebral malaria and rapidly decrease leukocyte accumulation in the brain.

Authors:  L Clemmer; Y C Martins; G M Zanini; J A Frangos; L J M Carvalho
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

5.  Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria.

Authors:  Elizabeth A Ashley; Kasia Stepniewska; Niklas Lindegardh; Anna Annerberg; Joel Tarning; Rose McGready; Lucy Phaiphun; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Eur J Clin Pharmacol       Date:  2010-03-19       Impact factor: 2.953

6.  Impaired clinical response in a patient with uncomplicated falciparum malaria who received poor-quality and underdosed intramuscular artemether.

Authors:  Valy Keoluangkhot; Michael D Green; Leonard Nyadong; Facundo M Fernández; Mayfong Mayxay; Paul N Newton
Journal:  Am J Trop Med Hyg       Date:  2008-04       Impact factor: 2.345

7.  Randomized controlled trial of artesunate or artemether in Vietnamese adults with severe falciparum malaria.

Authors:  Nguyen H Phu; Phung Q Tuan; Nicholas Day; Nguyen T H Mai; Tran T H Chau; Ly V Chuong; Dinh X Sinh; Nicholas J White; Jeremy Farrar; Tran T Hien
Journal:  Malar J       Date:  2010-04-15       Impact factor: 2.979

8.  Artesunate suppositories versus intramuscular artemether for treatment of severe malaria in children in Papua New Guinea.

Authors:  Harin A Karunajeewa; John Reeder; Kerry Lorry; Elizah Dabod; Juliana Hamzah; Madhu Page-Sharp; Gregory M Chiswell; Kenneth F Ilett; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

9.  Artemether bioavailability after oral or intramuscular administration in uncomplicated falciparum malaria.

Authors:  Kamolrat Silamut; Paul N Newton; Paktiya Teja-Isavadharm; Yupin Suputtamongkol; Duangsuda Siriyanonda; Maneerat Rasameesoraj; Sasithon Pukrittayakamee; Nicholas J White
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

10.  Effects of antimalarial drugs on movement of Plasmodium falciparum.

Authors:  Jaiaue Wongtanachai; Kamolrat Silamut; Nicholas P J Day; Arjen Dondorp; Urai Chaisri
Journal:  Southeast Asian J Trop Med Public Health       Date:  2012-01       Impact factor: 0.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.